Risperdal Breast Growth Lawsuits

Sponsored by Hissey-Kientz - Committed to protecting your legal rights.
Call us Toll Free at 866-275-4454 for a FREE Consultation
Help and information about Testosterone lawsuit issues.
Welcome

Kentucky settles Risperdal lawsuit

March 15th, 2016

The Commonwealth of Kentucky has settled a Risperdal lawsuit with the drug’s manufacturer for $15.5 million. The lawsuit alleged that Johnson & Johnson hid information about Risperdal side effects from doctors and patients while illegally marketing the drug for unapproved uses. read more »

Janssen ordered to pay $124 million after Supreme Court declines Risperdal lawsuit appeal

February 23rd, 2016

Johnson & Johnson subsidiary Janssen Pharmaceuticals has been ordered to pay $124 million to the state of South Carolina after the United States Supreme Court declined to hear an appeal by the company. The state of South Carolina filed a Risperdal lawsuit against the company, seeking civil penalties on two claims that alleged Janssen improperly marketed Risperdal and concealed its… read more »

Many consumers unaware of J&J’s illegal Risperdal actions

December 2nd, 2015

Author Steven Brill says he has been overwhelmed with letters and emails following the publication of a 15-chapter story on pharmaceutical giant Johnson & Johnson. He says many consumers were completely unaware of the company’s illegal practices regarding many of its drugs, including antipsychotic Risperdal, which Brill covers in the first chapter. read more »

Huffington Post publishes expose on Johnson & Johnson, Risperdal

November 25th, 2015

The Huffington Post has published a 15-chapter expose on American pharmaceutical giant Johnson & Johnson. The piece documents J & J’s troubling history of promoting antipsychotic Risperdal in its first chapter, including the sad tale of Austin Pledger, an autistic man who developed size 46DD breasts after taking Risperdal since age 12. read more »

Janssen Pharmaceuticals accused of hiding Risperdal side effects

November 18th, 2015

Janssen Pharmaceuticals and parent company Johnson & Johnson have been accused of hiding evidence of Risperdal side effects since 2003. The companies reportedly omitted information from a study that found a link between Risperdal and an increased risk of breast tissue growth among boys and male adolescents. read more »

Man responsible for illegal Risperdal marketing is now the CEO

November 11th, 2015

The Johnson & Johnson employee responsible for the illegal marketing of Risperdal to elderly and young boys while manipulating data is now the company’s CEO. Alex Gorsky was named the CEO of Johnson & Johnson in 2012 after he orchestrated the marketing and sales of the drug as Vice President from 1999 through 2005. read more »

Australian Therapeutic Goods Administration restricts Risperdal due to strokes

September 4th, 2015

Australia’s Therapeutic Goods Administration (the equivalent of the U.S. Food and Drug Administration) has restricted the use of Risperdal due to increased risks of strokes in patients. The TGA cited a study which found patients being treated with Risperdal for dementia other than Alzheimer’s were more than twice as likely to suffer from cerebrovascular events (strokes). Some doctors have expressed… read more »

Cherokee Nation files Risperdal lawsuit alleging misbranding

September 1st, 2015

The Cherokee Nation has filed a Risperdal lawsuit against manufacturers Johnson & Johnson and Janssen Pharmaceuticals alleging the companies misbranded and sold drugs for unapproved uses. The Nation says that J&J sold Risperdal to the Redbird Smith Health Center for several unapproved uses, including treatment of dementia in the elderly. In 2013, J&J paid more than $2.2 billion to the… read more »

Pediatrician says Risperdal manufacturers altered study

August 30th, 2015

The top pediatrician at a Canadian children’s hospital has accused Janssen Pharmaceuticals of altering a Risperdal study he co-authored in 2003. Doctor Denis Daneman says that the article he co-authored featured significant information about potential Risperdal side effects, but that the published version of the article omits that information. The integrity of the article was raised during a recent Risperdal… read more »

Long-term dosage of Risperdal could become more prevalent

July 27th, 2015

A randomized controlled trial found that patients who were given a 12-month injection of antipsychotic Risperdal were more likely to adhere to treatment, causing researchers to recommend the injection before the current oral pill method of ingestion. Patients who currently take Risperdal may be at a risk of side effects, including breast tissue growth in young boys. Risperdal has been… read more »

Contact Us Today for a Free Consultation.

I am currently represented by an attorney.
captcha
*Required fields